Ultragenyx Pharmaceutical Inc. (RARE) Stock Price & Analysis
Ultragenyx Pharmaceutical Inc. (RARE) fell 0.44% to USD 26.9 as of July 25, 2026 at 03:04 UTC, according to Nexqual real-time market data.
RARE last closed at USD 27.02; the session ranged USD 26.5–27.43 on volume of 1,434,076 shares. Market capitalization is $2.65B, with a 52-week range of USD 18.29–39.89 (NMS). Source: Nexqual, July 25, 2026 at 03:04 UTC.
Key Statistics (as of July 25, 2026 at 03:04 UTC)
| Price | USD 26.9 |
|---|---|
| Change | ▼ 0.44% (down) |
| Previous Close | USD 27.02 |
| Open | USD 27.32 |
| Day Range | USD 26.5 – 27.43 |
| 52-Week Range | USD 18.29 – 39.89 |
| Volume | 1,434,076 shares |
| Market Cap | $2.65B |
| Exchange | NMS |
Technical Analysis (RARE)
Nexqual's technical model rates RARE "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.7 (neutral) |
| vs SMA50 | Below (USD 27.31) |
| MACD | -0.09 (negative) |
Analyst Ratings (RARE)
Wall Street analysts rate RARE "Strong Buy" based on 19 analysts, with a mean price target of USD 53.37 (range USD 27–96), per Nexqual as of July 25, 2026 at 03:04 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 53.37 |
| High Target | USD 96 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 17 / 2 / 0 |
Earnings (RARE)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -1 |
| Revenue Estimate | $183.08M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.54 vs est -1.46 ▼ miss |
| 2025-12-31 | USD -1.29 vs est -1.17 ▼ miss |
| 2025-09-30 | USD -1.81 vs est -1.21 ▼ miss |
| 2025-06-30 | USD -1.17 vs est -1.32 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financials & Fundamentals (RARE)
| Total Revenue | $670.00M |
|---|---|
| Revenue Growth (YoY) | -2.20% |
| Gross Margin | -28.06% |
| Operating Margin | -102.21% |
| Profit Margin | -90.90% |
| Current Ratio | 2.02 |
| Total Cash | $413.00M |
| Total Debt | $1.20B |
| Free Cash Flow | $-219.09M |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financial Health Score (RARE)
Nexqual rates Ultragenyx Pharmaceutical Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:04 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $413M cash vs $1.20B debt |
| Cash Flow | Weak — FCF negative: -$219M, burning cash |
| Efficiency | Mixed — No data |
Ownership (RARE)
| Insider Ownership | +3.45% |
|---|---|
| Institutional Ownership | +102.03% |
| Shares Outstanding | 98.49M |
| Float | 94.51M |
| Short % of Float | +17.03% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Leadership (RARE)
Ultragenyx Pharmaceutical Inc. is led by Emil D. Kakkis (age 65), Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 03:04 UTC.
| Founder, President, CEO & Director | Emil D. Kakkis (age 65) |
|---|---|
| Executive VP of Corporate Strategy & CFO | Howard Horn (age 46) |
| Senior Vice President of Business Development & Alliance Management | Vimal Srivastava (age 60) |
Major Backers & Investors (RARE)
Notable institutional backers of Ultragenyx Pharmaceutical Inc. include AQR Capital Management, LLC, RTW Investments LP, Sands Capital Management, LLC, according to Nexqual as of July 25, 2026 at 03:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AQR Capital Management, LLC | 4.65% |
| RTW Investments LP | 3.7% |
| Sands Capital Management, LLC | 3.26% |
| Sofinnova Investments, Inc. | 3.19% |
| Wellington Management | 2.68% |
| Bellevue Group AG | 2.42% |
| AQR Funds-AQR Long-Short Equity Fund | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.89% |
| State Street | 8.81% |
| BlackRock | 8.09% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
From Ultragenyx Pharmaceutical Inc.'s Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
- Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease.
- The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTCT | PTC Therapeutics, Inc. | USD 76.82 | ▼ 2.02% |
| AGIO | Agios Pharmaceuticals, Inc. | USD 36.36 | ▲ 0.86% |
| DNLI | Denali Therapeutics Inc. | USD 23.11 | ▼ 2.24% |
| RGNX | REGENXBIO Inc. | USD 9.73 | ▼ 4.61% |
| QURE | uniQure N.V. | USD 38.97 | ▼ 3.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:04 UTC. This page is informational and not investment advice.